Access cutting-edge multiple myeloma treatment through this clinical trial at a research site in Philadelphia. Study-provided care at no cost to qualified participants.
Access multiple myeloma specialists in Philadelphia at no cost
This study follows strict safety protocols and ethical guidelines
All study-related multiple myeloma treatment provided free
This study is researching an investigational drug called linvoseltamab ("study drug") in participants at moderate risk of developing multiple myeloma (about 3 to 10% average annual risk), a group that consists of patients with precancerous conditions called High-Risk Monoclonal Gammopathy of Undetermined Significance (HR-MGUS) and Non-High-Risk Smoldering Multiple Myeloma (NHR-SMM). The primary purpose of the study is to understand how well the study drug can eliminate abnormal plasma cells and
Sponsor: Regeneron Pharmaceuticals
Check if you qualify for this multiple myeloma clinical trial in Philadelphia, PA
If you're searching for multiple myeloma treatment options in Philadelphia, PA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Philadelphia research site is actively enrolling participants for this clinical trial. You'll receive care from experienced multiple myeloma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.